Drug-related mortality and its impact on adult mortality in eight European countries

被引:133
作者
Bargagli, AM
Hickman, M
Davoli, M
Perucci, CA
Schifano, P
Buster, M
Brugal, T
Vicente, J
机构
[1] ASL Rome E, Dept Epidemiol, I-00198 Rome, Italy
[2] Univ London Imperial Coll Sci Technol & Med, Ctr Res Drugs & Hlth Behav, London, England
[3] Municipal Hlth Serv, Dept Epidemiol, Amsterdam, Netherlands
[4] IMS, Epidemiol Serv, Barcelona, Spain
[5] European Monitoring Ctr Drugs & Drug Addict, Dept Epidemiol, Lisbon, Portugal
基金
英国医学研究理事会;
关键词
drug-related mortality; longitudinal studies; opiate addiction;
D O I
10.1093/eurpub/cki168
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective: To estimate the mortality rates from drug-related deaths and other causes among problem drug users and population attributable risk of death due to opiate use in eight study sites in Europe. Methods: Opiate users were recruited from drug treatment centres during the period 1990-1998 and deaths followed up through national or local mortality registries. Gender-specific overall mortality rate, proportion of deaths by cause (drug-related, HIV, other), standardized mortality ratios (SMRs), and the attributable risk fraction (ARF) were estimated. Results: Crude mortality rates varied from 1 per 100 person-years in the Dublin and London cohorts to 3.8 per 100 person-years in Barcelona. The highest drug-related mortality rate was 10 per 1000 person-years in Barcelona; the rates were similar to 7 per 1000 person-years in Denmark, London, Rome, and Vienna, and < 3.5 per 1000 person-years for the others cohorts. The mortality rate for AIDS was < 2 per 1000 person-years in all the cohorts except Lisbon, Rome, and Barcelona, for which it was similar to 6 per 1000 person-years. The highest SMR among males was 21.1 in Barcelona, and among females the highest SMRs were 53.7 and 37.7 in Barcelona and Rome, respectively. In Denmark the ARF was 5%, whereas it was > 10% in all other study sites and 24% in Barcelona. Conclusion: Cohort mortality studies, especially in combination with estimates of prevalence, provide useful insights into the impact of opiate use on mortality across European countries and emphasize how preventing overall and drug-related deaths among opiate users can significantly improve the health of the population.
引用
收藏
页码:198 / 202
页数:5
相关论文
共 30 条
[1]   Mortality among problem drug users in Rome: an 18-year follow-up study, 1980-97 [J].
Bargagli, AM ;
Sperati, A ;
Davoli, M ;
Forastiere, F ;
Perucci, CA .
ADDICTION, 2001, 96 (10) :1455-1463
[2]   A small area analysis estimating the prevalence of addiction to opioids in Barcelona, 1993 [J].
Brugal, MT ;
Domingo-Salvany, A ;
Maguire, A ;
Caylà, JA ;
Villalbi, JR ;
Hartnoll, R .
JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 1999, 53 (08) :488-494
[3]   Estimating the number of opiate users in Amsterdam by capture recapture: The importance of case definition [J].
Buster, MCA ;
van Brussel, GHA ;
van den Brink, W .
EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2001, 17 (10) :935-942
[4]   THE MEDICAL COMPLICATIONS OF DRUG-ADDICTION AND THE MEDICAL ASSESSMENT OF THE INTRAVENOUS-DRUG-USER - 25 YEARS LATER [J].
CHERUBIN, CE ;
SAPIRA, JD .
ANNALS OF INTERNAL MEDICINE, 1993, 119 (10) :1017-1028
[5]   A capture-recapture study of the prevalence and implications of opiate use in Dublin [J].
Comiskey, CM ;
Barry, JM .
EUROPEAN JOURNAL OF PUBLIC HEALTH, 2001, 11 (02) :198-200
[6]   THE IMPACT OF DRUG-RELATED DEATHS ON MORTALITY AMONG YOUNG-ADULTS IN MADRID [J].
DELAFUENTE, L ;
BARRIO, G ;
VICENTE, J ;
BRAVO, MJ ;
SANTACREU, J .
AMERICAN JOURNAL OF PUBLIC HEALTH, 1995, 85 (01) :102-105
[7]   PROGRESS AGAINST CANCER - AN EPIDEMIOLOGIC ASSESSMENT - THE 1991 CASSEL,JOHN,C. MEMORIAL LECTURE [J].
DOLL, R .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1991, 134 (07) :675-688
[8]  
English DR., 1995, QUANTIFICATION DRUG
[9]   MORTALITY IN PATIENTS WITH SUBSTANCE-ABUSE - A FOLLOW-UP IN STOCKHOLM COUNTY, 1973-1984 [J].
ENGSTROM, A ;
ADAMSSON, C ;
ALLEBECK, P ;
RYDBERG, U .
INTERNATIONAL JOURNAL OF THE ADDICTIONS, 1991, 26 (01) :91-106
[10]  
*EUR MON CTR DRUGS, 2002, NAT PREV EST PROBL U